新药时代双表达弥漫大B细胞淋巴瘤的治疗探索

王婕; 牛挺

doi:10.13201/j.issn.1004-2806.2024.09.004

新药时代双表达弥漫大B细胞淋巴瘤的治疗探索

王婕¹,
牛挺^1, ,

- 四川大学华西医院血液内科(成都，610041)

详细信息

作者简介:
牛挺,医学博士,主任医师,教授,博士生导师,博士后合作导师。担任四川大学华西医院血液内科主任,四川大学生物治疗全国重点实验室及生物治疗协同创新中心主要研究者(PI),转化医学国家重大科技基础设施(四川)主要研究者(PI),中华医学会血液学分会常委,淋巴细胞疾病学组副组长,中国血液病专科联盟副理事长,中国STAR工作组血液病学专科委员会主任委员,中华医学会《国际输血及血液学杂志》副总编辑,国家药品监督管理局药品审评中心及医疗器械技术审评中心外聘专家,国家血液病临床医学研究中心(NCRCH)四川省分中心主任,国家血液内科专业质量控制中心(筹)工作组专家,淋浆细胞疾病工作组副组长,四川省肿瘤学会副理事长,血液肿瘤分会主任委员,四川省干细胞技术与细胞治疗协会副会长,血液学分会会长,四川省医学会血液学分会候任主任委员,四川省血液内科医疗质量控制中心业务主任。

通讯作者: 牛挺，E-mail：niuting@wchscu.cn

中图分类号: R733.4

收稿日期: 2024-05-27

刊出日期: 2024-09-01

Therapeutic exploration of double-expressor diffuse large B-cell lymphoma in the era of new drugs

WANG Jie¹,
NIU Ting^1, ,

- Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China

More Information

Corresponding author: NIU Ting, E-mail: niuting@wchscu.cn

Received Date: 27 May 2024

Publish Date: 01 September 2024

摘要

摘要: 双表达MYC和BCL2是弥漫大B细胞淋巴瘤独立的预后因素，双表达淋巴瘤对标准的一线治疗方案R-CHOP反应不佳，5年总体生存率和无进展生存率显著缩短。如何提高和改善双表达淋巴瘤患者生存是临床上弥漫大B细胞淋巴瘤治疗的难点之一，迫切需要开发新型靶向药物和创新性疗法。在新药时代，针对双表达淋巴瘤的治疗探索正不断深入。本文根据新药的种类，介绍了针对双表达淋巴瘤开展的新药研究和治疗探索。
- 双表达 /
- 弥漫大B细胞淋巴瘤 /
- 新药治疗 /
- 临床试验
Abstract: Double-expressor of MYC and BCL2 is an independent prognostic factor for diffuse large B-cell lymphoma, and double-expressor lymphoma responds poorly to the standard first-line treatment regimen R-CHOP, with a significant shortening of 5-year overall survival and progression free survival. How to improve the survival of patients with double-expressor lymphoma is one of the difficulties in the treatment of diffuse large B-cell lymphoma in clinical practice, and there is an urgent need for the development of novel targeting agents and innovative therapies. In the era of new drugs, the therapeutic exploration of double-expressor lymphoma has been deepening, and this article introduces new drug clinical trials and therapeutic explorations carried out for double-expressor lymphoma based on the types of new drugs.
- double-expressor /
- diffuse large B-cell lymphoma /
- new drug therapy /
- clinical trial

HTML全文

参考文献(39)

[1]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
[2]	Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in china, 2004-2017: an observational study[J]. J Hematol Oncol, 2019, 12(1): 22. doi: 10.1186/s13045-019-0706-9
[3]	Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?[J]. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 366-378. doi: 10.1182/asheducation-2016.1.366
[4]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
[5]	Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment[J]. Cancer, 2018, 124(24): 4622-4632. doi: 10.1002/cncr.31646
[6]	Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program[J]. Blood, 2013, 121(20): 4021-4031;quiz 4250. doi: 10.1182/blood-2012-10-460063
[7]	Bartlett NL, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase Ⅲ Intergroup Trial Alliance/CALGB 50303[J]. J Clin Oncol, 2019, 37(21): 1790-1799. doi: 10.1200/JCO.18.01994
[8]	Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications[J]. Int J Biol Sci, 2014, 10(7): 757-770. doi: 10.7150/ijbs.9067
[9]	Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications[J]. Clin Cancer Res, 2009, 15(12): 3947-3957. doi: 10.1158/1078-0432.CCR-08-2787
[10]	Guan XW, Wang HQ, Ban WW, et al. Novel HDAC inhibitor chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20[J]. Cell Death Dis, 2020, 11(1): 20. doi: 10.1038/s41419-019-2210-0
[11]	Ridwansyah H, Wijaya I, Bashari MH, et al. The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review[J]. Biomol Biomed, 2023, 23(5): 727-739.
[12]	Zhang MC, Fang Y, Wang L, et al. Clinical efficacy and molecular biomarkers in a phase Ⅱ study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma[J]. Clin Epigenetics, 2020, 12(1): 160. doi: 10.1186/s13148-020-00948-9
[13]	Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation[J]. J Clin Oncol, 2017, 35(1): 24-31. doi: 10.1200/JCO.2016.68.2740
[14]	Herrera AF, Mei M, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1046-1053. doi: 10.1016/j.bbmt.2015.02.005
[15]	Ji J, Liu Z, Kuang P, et al. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas[J]. Int J Cancer, 2021, 149(12): 2075-2082. doi: 10.1002/ijc.33761
[16]	Chen Y, Wang X, Xiang W, et al. Development of purine-based hydroxamic acid derivatives: Potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities[J]. J Med Chem, 2016, 59(11): 5488-5504. doi: 10.1021/acs.jmedchem.6b00579
[17]	王婕, 赵艾琳, 李赫, 等. 新型Ⅰ类和Ⅱb类选择性HDAC抑制剂甲磺酸普依司他治疗弥漫大B细胞淋巴瘤的体外药效学和作用机制研究[J]. 中华血液学杂志, 2022, 48(9): 753-759.
[18]	Jie Wang, He Li, Linyu Yang, et al. Phase 1 safety and dose escalation of purinostat mesylate, a uniquely potent and selective inhibitor of HDAC Ⅰ and Ⅱb in relapsed or refractory lymphoma and multiple myeloma[J]. Blood, 2022, 140(Supplement 1): 6612-6613. doi: 10.1182/blood-2022-167079
[19]	Lijuan Chen, Linyu Yang, Jie Wang, et al. HDAC Ⅰ/Ⅱb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase Ⅱa trial[J]. J Clin Oncol, 2024, 42(17_suppl), https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA7074. doi: 10.1200/JCO.2024.42.17_suppl.LBA7074
[20]	Bogusz AM, Kovach AE, Le LP, et al. Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence[J]. PLoS One, 2017, 12(2): e0172364. doi: 10.1371/journal.pone.0172364
[21]	Johnson PWM, Balasubramanian S, Hodkinson B, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 phoenix trial[J]. Blood Adv, 2023, 7(10): 2008-2017. doi: 10.1182/bloodadvances.2022009389
[22]	Younes A, Sehn LH, Johnson P, et al. Randomized phase Ⅲ trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(15): 1285-1295. doi: 10.1200/JCO.18.02403
[23]	Jia Jin, Yalan Wang, Xi Wang, et al. Zanubrutinib combined with R-CHOP in previously untreated non-germinal center B-cell(GCB)diffuse large B-cell lymphoma(DLBCL)patients with BCL2 and MYC protein co-expression: A multicenter, phase Ⅱ study[J]. Blood, 2023, 142(Supplement 1): 4468. doi: 10.1182/blood-2023-181529
[24]	Yang Yang, Jingsong He, Yi Zhao, et al. Preliminary outcomes of orelabrutinib plus R-CHOP in treatment-naive patients with double-expression diffuse large B-cell lymphoma[J]. Blood, 2023, 142(Supplement 1): 6222. doi: 10.1182/blood-2023-187906
[25]	Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804. doi: 10.1016/S0140-6736(19)31774-X
[26]	Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma[J]. N Engl J Med, 2022, 386(4): 351-363. doi: 10.1056/NEJMoa2115304
[27]	Franck Morschhauser, Yanwen Jiang, Fabrice Jardin, et al. Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma(DLBCL)from the polarix trial[J]. J Clin Oncol, 2022, 40(16_suppl), https://doi.org/10.1200/JCO.2022.40.16_suppl.7517. doi: 10.1200/JCO.2022.40.16_suppl.7517
[28]	Melchor J, Garcia-Lacarte M, Grijalba SC, et al. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma[J]. J Immunother Cancer, 2023, 11(2): e006113. doi: 10.1136/jitc-2022-006113
[29]	Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma[J]. Blood, 2021, 137(5): 600-609. doi: 10.1182/blood.2020006578
[30]	Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1): 31-42. doi: 10.1016/S1470-2045(18)30864-7
[31]	Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma[J]. N Engl J Med, 2022, 386(7): 640-654. doi: 10.1056/NEJMoa2116133
[32]	Ying Z, Yang H, Guo Y, et al. Relmacabtagene autoleucel(relma-cel)CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in china[J]. Cancer Med, 2021, 10(3): 999-1011. doi: 10.1002/cam4.3686
[33]	Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the us lymphoma CAR T consortium[J]. J Clin Oncol, 2020, 38(27): 3119-3128. doi: 10.1200/JCO.19.02104
[34]	Sesques P, Ferrant E, Safar V, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center[J]. Am J Hematol, 2020, 95(11): 1324-1333. doi: 10.1002/ajh.25951
[35]	Joanna Zurko, Geoffrey Shouse, Pallawi Torka. Double hit/double expressor lymphomas: A multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy[J]. Blood, 2022, 140(Supplement 1): 375-377. doi: 10.1182/blood-2022-163438
[36]	Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma(SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial[J]. Lancet Haematol, 2020, 7(7): e511-e522. doi: 10.1016/S2352-3026(20)30120-4
[37]	Zhang LH, Kosek J, Wang M, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression[J]. Br J Haematol, 2013, 160(4): 487-502. doi: 10.1111/bjh.12172
[38]	Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma[J]. Cancer Cell, 2012, 21(6): 723-737. doi: 10.1016/j.ccr.2012.05.024
[39]	Godfrey JK, Nabhan C, Karrison T, et al. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2[J]. Cancer, 2019, 125(11): 1830-1836. doi: 10.1002/cncr.31877